Please assess the completion status of the following clinical trial:

Trial Title: Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has completed a colonoscopy according to the AGA criteria, with no clinically significant findings~* Patient has successfully completed protocol procedures (with no clinically significant findings): physical exam, 12-lead ECG, or clinical laboratory tests~* Patient meets protocol criteria for diagnosis of IBS-C~* Patient demonstrates continued IBS-C through Pretreatment Period~* Patient is compliant with IVRS~Exclusion Criteria:~* Patient has history of loose or watery stools~* Patient has symptoms of or been diagnosed with a medical condition that may contribute to abdominal pain~* Patient has a structural abnormality of the gastrointestinal (GI) tract or a disease or condition that can affect GI motility~* Patient has any protocol-excluded or clinically significant medical or surgical history that could confound the study assessments

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- 290 μg Linaclotide (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).